Oak Hill Bio Enters an Exclusive Licensing Agreement with Roche for Rugonersen
Shots:
- Oak Hill Bio has entered into an exclusive license agreement with Roche to obtain global rights of rugonersen (RO7248824) for the treatment of angelman syndrome
- Oak Hill to initiate a pivotal P-III trial of rugonersen for angelman syndrome in early 2026, pending regulatory review of the final trial protocol
- TANGELO study led by Roche, assessed rugonersen (ASO) vs natural history, which showed positive exploratory effects on multiple clinical measures & EEG delta power; data was presented at FAST’s Global Science Summit 2024
Ref: Oak Hill Bio | Image: Oak Hill Bio & Roche
Related News:- Roche's Columvi (Glofitamab) Regimen Receives the EC’s Approval to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
